Company intelligence / Profile preview

Alkermes

Ownership: Public · ALKS
Employees: ~1800
Development stage: Commercial

Overview

Alkermes has four approved drugs on the market for psychiatric and addiction indications. Its late-stage pipeline includes a pediatric formulation of olanzapine/samidorphan in Phase 3 for schizophrenia/bipolar I disorder and an orexin agonist program (ALKS 2680) in Phase 2 for sleep disorders. Additional preclinical programs target central nervous system diseases. The company recently divested its oncology business to focus on neuroscience.

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculesextended-release injectablesoral drugs
Industry: Biotech

Drug pipeline

20 assets

naltrexone

Approved

19 more assets in the full pipeline.

Partnerships

Novo Nordisk (sale of manufacturing facility)previously with Janssen/J&J for RISPERDAL CONSTA®

Financials

Market cap: $7.5B
Total revenue: $1.5B
Enterprise value: $8.3B

Beyond the preview

Go deeper on Alkermes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alkermes.